A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study.

Autor: Petzer, Andreas L., Sperr, Wolfgang R., Buxhofer-Ausch, Veronika, Sliwa, Thamer, Schmidt, Stefan, Greil, Richard, Wölfler, Albert, Pichler, Petra, Dormann, Clemens, Burgstaller, Sonja, Tinchon, Christoph, Lang, Alois, Goebel, Florian, Uthman, Shanow, Muenchmeier, Niklas, Valent, Peter
Zdroj: Wiener Klinische Wochenschrift; Aug2020, Vol. 132 Issue 15/16, p415-422, 8p
Abstrakt: Summary: Background: Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML) showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an improved long-term survival and progression-free survival. This study assessed whether patients achieving early treatment response (ETR; partial cytogenetic response or BCR-ABL1 mRNA ≤10% at 3 months) in daily practice also have a long-term survival benefit. Methods: The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-EFECT), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clinical practice. The primary aim was to assess the 5‑year overall survival rate. Results: Of the 211 patients from 12 centers across Austria (January 2004–May 2010), 176 (median age, 56 years) were included in the analysis. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR− group). The ETR+ group had higher 5‑year overall survival (92.5% vs. 77.5%, P = 0.018) and progression-free survival (95.6% vs. 87.5%, P = 0.06) rates compared with the ETR− group. As expected, more patients in the ETR− group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib). Conclusion: The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clinical routine. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: